First patient enrolled under newly modified protocol in CytoDyn’s phase 3 PRO 140 trial
CytoDyn announced enrollment of the first patient under a recently modified protocol in the Company’s Phase 3 combination study with PRO 14O (humanized monoclonal antibody to CCR5). The modified protocol has been cleared by the FDA and features a 50% reduction in enrollment to 150 subjects. July 26, 2016